Squarepoint’s TG Therapeutics TGTX Stock Holding History

Squarepoint’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.06M	Buy	+55,700	New	+$2.28M	﹤0.01%	1995
2026 Q1	–	Sell	-7,000	Closed	-$209K	–	4965
2025 Q4	$209K	Sell	7,000 -1,800	-20%	-$58.8K	﹤0.01%	3845
2025 Q3	$318K	Sell	8,800 -5,800	-40%	-$191K	﹤0.01%	3619
2025 Q2	$525K	Sell	14,600 -100	-0.7%	-$3.72K	﹤0.01%	3234
2025 Q1	$580K	Sell	14,700 -34,700	-70%	-$1.17M	﹤0.01%	3155
2024 Q4	$1.49M	Buy	+49,400	New	+$1.42M	﹤0.01%	2689

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Squarepoint's TGTX Position: Q2 2026 in Review

Squarepoint reduced its TG Therapeutics (TGTX) stake by 68% in Q2 2026, selling an estimated $14.2M and leaving 166,975 shares worth $9.17M. The position accounts for 0.01% of the portfolio, ranked #1154.

Squarepoint first reported a position in TGTX in Q4 2015 and has held it in 23 quarters since. The position peaked at $25.4M in Q4 2025. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Squarepoint held 166,975 shares of TG Therapeutics worth $9.17M as of Q2 2026.
Squarepoint sold 346,838 TG Therapeutics shares in Q2 2026, an estimated $14.2M.
TG Therapeutics made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1154 holding.
Squarepoint first reported a position in TG Therapeutics in Q4 2015 and has held it in 23 quarters since.
Squarepoint's TG Therapeutics position peaked at $25.4M in Q4 2025.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.